Clinical Trial Update: Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating ponatinib hydrochloride as second-line therapy for chronic myeloid leukemia in chronic phase patients resistant or intolerant to i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Iclusig (ponatinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia | Phase 2 | Status: RECRUITING